Gut microbiota and pediatric obesity/non-alcoholic fatty liver disease

J Formos Med Assoc. 2019 Mar:118 Suppl 1:S55-S61. doi: 10.1016/j.jfma.2018.11.006. Epub 2018 Dec 1.

Abstract

Huge amount microorganisms resides in human intestine, and many contribute to the maturation and homeostasis of immune system. The diversity of gut ecology are affected by the gestational age, delivery type, feeding sources, and antibiotics use in neonates. Recent studies pointed out that disturbance of gut microbiota, so called dysbiosis, could result in several pediatric diseases including obesity, non-alcoholic fatty liver disease (NAFLD), metabolic syndromes, allergic diseases, and inflammatory bowel diseases. However, there are no single species can be proven to play a key factor in pediatric obesity and NAFLD at present. Various probiotics may confer benefit to these gut microbiota-related pediatric diseases. The clinical application is still limited. This review article aimed to elucidate evidently the relationship between gut microbiota and pediatric obesity/NAFLD and to discuss the potential probiotics use in pediatric obesity and NAFLD.

Keywords: Immunity; Microbiota; Non-alcoholic fatty liver disease; Obesity; Probiotics.

Publication types

  • Review

MeSH terms

  • Child
  • Dysbiosis
  • Gastrointestinal Microbiome*
  • Host-Pathogen Interactions
  • Humans
  • Non-alcoholic Fatty Liver Disease / microbiology*
  • Non-alcoholic Fatty Liver Disease / therapy
  • Pediatric Obesity / microbiology*
  • Pediatric Obesity / therapy
  • Probiotics / therapeutic use
  • Randomized Controlled Trials as Topic